Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Systematic Screening Identifies Dual PI3K and mTOR Inhibition as a Conserved Therapeutic Vulnerability in Osteosarcoma

10 Apr 2015

Abstract excerpt

PURPOSE: Osteosarcoma is the most common cancer of bone occurring mostly in teenagers. Despite rapid advances in our knowledge of the genetics and cell biology of osteosarcoma, significant improvements in patient survival have not been observed. The identification of effective therapeutics has been largely empirically based. The identification of new therapies and therapeutic targets are urgently needed to enable...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to PI3K/AKT/mTOR signaling in cancer
Share to Sarcoma Diagnosis and Treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 25862761
DOI: 10.1158/1078-0432.ccr-14-3026

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Systematic Screening Identifies Dual PI3K and mTOR Inhibition as a Conserved Therapeutic Vulnerability in OsteosarcomaPMID 25862761Read ↗

Emerging concepts for PI3K/mTOR inhibition as a potential treatment for osteosarcomaSemantic proximity Read ↗

Complementary genomic approaches highlight the PI3K/mTOR pathway as a common vulnerability in osteosarcomaSemantic proximity Read ↗

Functional genome screen for therapeutic targets of osteosarcomaSemantic proximity Read ↗

A Sleeping Beauty Screen Highlights Cancer Drivers in Osteosarcoma.Semantic proximity Read ↗

Molecular Biology of OsteosarcomaSemantic proximity Read ↗

Advances in Target Therapy Research in OsteosarcomaSemantic proximity Read ↗

A cross-species drug discovery pipeline to identify and validate new treatments for osteosarcomaSemantic proximity Read ↗

Novel insights and therapeutic interventions for pediatric osteosarcoma.Semantic proximity Read ↗

Molecular genetics of osteosarcoma.Semantic proximity Read ↗

Murine models of osteosarcoma: A piece of the translational puzzleSemantic proximity Read ↗

Osteosarcoma Genetics and Epigenetics: Emerging Biology and Candidate TherapiesSemantic proximity Read ↗

Targeted inhibition of SCFSKP2 confers anti-tumor activities resulting in a survival benefit in osteosarcomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.